SGO Annual Meeting | Conference

Dr. Matulonis on the Results of the Phase 3 SORAYA Trial in Platinum-Resistant Ovarian Cancer

March 21st 2022

Ursula A. Matulonis, MD, discusses the results of the phase 3 SORAYA trial in platinum-resistant ovarian cancer.

Dr. Lara on Role of Molecular Differences in Disparities in Uterine Serous Carcinoma

March 21st 2022

Oliva Lara, MD, discusses the connection between molecular differences and disparities in cancer care in uterine serous carcinomas, as examined in a retrospective cohort study.

Maintenance Niraparib Given at Individualized Starting Dose Improves PFS in Ovarian Cancer

March 20th 2022

When maintenance niraparib was administered at an individualized starting dose, it resulted in a statistically significant and clinically meaningful improvement in progression-free survival vs placebo in patients with newly diagnosed ovarian cancer, irrespective of biomarker status.

Maintenance Selinexor Improves PFS Vs Placebo in Advanced or Recurrent Endometrial Cancer

March 20th 2022

Maintenance selinexor monotherapy was found to improve progression-free survival over placebo in patients with advanced or recurrent endometrial cancer.

IP Carboplatin/Paclitaxel Improves PFS, But Not OS, Vs IV Chemo in Ovarian Cancer

March 20th 2022

The use of intraperitoneal carboplatin with paclitaxel improved progression-free survival, but not overall survival, vs intravenous chemotherapy in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Mirvetuximab Soravtansine Elicits Encouraging ORR in FRα-High, Platinum-Resistant Ovarian Cancer

March 20th 2022

Mirvetuximab soravtansine was found to produce clinically meaningful antitumor activity with acceptable safety and tolerability in patients with platinum-resistant ovarian cancer and high folate receptor–alpha (FRα) expression.

Nemvaleukin Alfa/Pembrolizumab Combo Shows Promising Activity in Platinum-Resistant Ovarian Cancer

March 19th 2022

The combination of nemvaleukin alpha and pembrolizumab led to encouraging clinical activity in patients with pretreated ovarian cancer who are resistant to platinum-based chemotherapy.

Atezolizumab Plus Chemoradiation Triggers T-Cell Clonal Expansion in Locally Advanced Cervical Cancer

March 19th 2022

Atezolizumab given as an immune primer or concurrently with extended field chemoradiation demonstrated favorable progression-free survival and few dose-limiting toxicities, with evidence of T-cell clonal expansion in the tumors and peripheral blood of patients with locally advanced, node-positive cervical cancer.

Neoadjuvant Niraparib Shows Early Promise in BRCA-Mutated, HRD+ Ovarian Cancer

March 19th 2022

Neoadjuvant niraparib induced strong results for patients with BRCA-mutant, homologous repair deficient–positive advanced resectable ovarian cancer.

Niraparib Plus Bevacizumab Shows Promise in High-Risk Ovarian Cancer Population

March 19th 2022

Niraparib in combination with bevacizumab was efficacious following 1 line of platinum-based chemotherapy among patients with newly diagnosed advanced ovarian cancer, regardless of biomarker status.

Intravenous Chemo/Bevacizumab Shows Comparable Survival Outcomes Vs Intraperitoneal Regimen in Advanced Ovarian Cancer

March 19th 2022

Intravenous chemotherapy plus bevacizumab did not demonstrate differences in progression-free and overall survival compared with intraperitoneal chemotherapy plus bevacizumab in patients with advanced ovarian cancer with no macroscopic disease.

Olaparib Shows Comparable OS to Chemotherapy in BRCA+, Platinum-Sensitive, Relapsed Ovarian Cancer

March 19th 2022

Single-agent olaparib generated similar overall survival compared with non-platinum chemotherapy in heavily pretreated patients with platinum-sensitive, relapsed ovarian cancer with BRCA mutations, according to the final analysis of the phase 3 SOLO3 trial.

PRO Data Support the Use of Pembrolizumab Combo in Persistent, Recurrent, or Metastatic Cervical Cancer

March 19th 2022

Patient-reported outcome data support a favorable benefit/risk profile for the combination of pembrolizumab plus chemotherapy, with or without bevacizumab, in patients with persistent, recurrent, or metastatic cervical cancer.

Dr. Zakhour on the Utilization of Tisotumab Vedotin in Cervical Cancer

March 19th 2022

Mae Zakhour, MD, discusses the utilization of tisotumab vedotin-tftv in cervical cancer.

Dr. Frimer on the Exploration of Maintenance with Niraparib in Uterine Serous Carcinoma

March 19th 2022

Marina Frimer, MD, FACOG, FACS, discusses the exploration of maintenance with niraparib in a phase 2 trial in patients with advanced or platinum-sensitive recurrent uterine serious carcinoma

A Variety of Clinical and Molecular Factors Mark Long-Term PFS in PSR OC Treated with Olaparib

March 18th 2022

Patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation treated with maintenance olaparib who achieved long-term progression-free survival more often had homologous recombination deficiency-positive tumors compared with those who experienced a short-term PFS.

Olaparib Maintenance After Response to First-Line Chemo Under Exploration in BRCA Wild-Type Advanced Ovarian Cancer

March 18th 2022

Maintenance therapy with olaparib will be examined in patients with BRCA1/2 wild-type advanced ovarian cancer who responded to first-line, platinum-based chemotherapy in the phase 3 MONO-OLA1 trial.

Phase 3 Trial Seeks to Confirm Oregovomab Benefit in Advanced Ovarian Cancer

March 18th 2022

Oregovomab, an investigational monoclonal antibody with promising phase 2 data, is being tested in combination with paclitaxel for patients with advanced epithelial ovarian cancer in the phase 3 FLORA-5 trial.

Ociperlimab/Tislelizumab Combo Under Exploration in Previously Treated Recurrent or Metastatic Cervical Cancer

March 18th 2022

The addition of ociperlimab to tislelizumab is under investigation in the phase 2 AdvanTIG-202 trial in patients with previously treated recurrent or metastatic cervical cancer.

Antolitinic/Sintilimab Combination Under Investigation for OCCC in China

March 18th 2022

Chinese investigators have launched CC-ANNIE, a phase 2 trial exploring anlotinib plus sintilimab for women with recurrent platinum-resistant ovarian clear cell carcinoma.